Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease

BACKGROUND: Combining advanced therapies may improve outcomes in inflammatory bowel disease (IBD), but there are little data on the effectiveness and safety of this approach. METHODS: We examined outcomes of patients who received vedolizumab in combination with another biologic or tofacitinib betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Llano, Ernesto M, Shrestha, Shreeju, Burstein, Ezra, Boktor, Moheb, Fudman, David I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802270/
https://www.ncbi.nlm.nih.gov/pubmed/36776641
http://dx.doi.org/10.1093/crocol/otab030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802270/
https://www.ncbi.nlm.nih.gov/pubmed/36776641
http://dx.doi.org/10.1093/crocol/otab030

Ejemplares similares